Treatment of hepatic veno-occlusive disease after bone marrow transplantation with recombinant human tissue plasminogen activator (rh-tPA)

A. Yoshimi, K. Kato, N. Maeda, T. Matsuyama, S. Kojima

研究成果: Contribution to journalArticle査読

4 被引用数 (Scopus)

抄録

Ten children were treated with recombinant human tissue plasminogen activator (rh-tPA) for severe hepatic veno-occlusive disease (VOD) that developed after bone marrow transplantation. Treatment with rh-tPA was begun a median of 22 days (range; 13-127 days) after transplantation. Seven of 9 (78%) evaluable patients had complete resolution of their VOD. Four patients had hemorrhagic complications, and 2 of them died because of pulmonary hemorrhage and subdural hemorrhage, respectively. Although rh-tPA seems to be an effective therapy for established VOD, further studies will be necessary to determine its safety as well as the optimal dosing regimen.

本文言語英語
ページ(範囲)103-108
ページ数6
ジャーナル[Rinshō ketsueki] The Japanese journal of clinical hematology
41
2
出版ステータス出版済み - 2 2000
外部発表はい

All Science Journal Classification (ASJC) codes

  • Medicine(all)

フィンガープリント 「Treatment of hepatic veno-occlusive disease after bone marrow transplantation with recombinant human tissue plasminogen activator (rh-tPA)」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル